Scale has invested in Inspiren's $100M Series B funding round to support the development of its AI-powered platform that enhances safety and care quality in senior living communities.

Information on the target

Scale is excited to announce our investment in Inspiren’s $100M Series B funding round. Inspiren is at the forefront of transforming senior living communities by integrating technology that enhances safety and care quality for older adults. Their innovative platform unifies resident safety, care planning, staffing, and emergency response into a single, AI-powered solution, addressing the growing demand for effective care as the aging population increases.

As the demographic landscape shifts, with projections indicating that by 2030, one in five Americans will be aged 65 or older, Inspiren's technology is essential for senior living facilities to meet the challenges of this demographic change. By providing real-time insights into resident behavior, Inspiren empowers care teams to deliver informed and timely care, ultimately leading to safer environments for residents and improved operational efficiency for communities.

Industry overview in the target’s specific country

The senior living industry in the United States is undergoing significant transformation, driven by demographic shifts and technological advancements. With an increasing number of older adults requiring specialized care, the demand for innovative solutions

View Source

Similar Deals

Oak HC/FT, General Catalyst Chai Discovery

2025

Series B Biotechnology & Medical Research (NEC) United States of America
Oak HC/FT Chai Discovery

2025

Series B Biotechnology & Medical Research (NEC) United States of America
Redpoint Ventures Function Health

2025

Series B Medical & Diagnostic Laboratories United States of America
Five Elms Capital Ritten

2025

Series B Healthcare Facilities & Services (NEC) United States of America
Reach Capital Manifold

2025

Series B Biotechnology & Medical Research (NEC) United States of America
ARCH Venture Partners, GV (Google Ventures) Pelage Pharmaceuticals

2025

Series B Proprietary & Advanced Pharmaceuticals United States of America

Scale

invested in

Inspiren

in 2023

in a Series B deal

Disclosed details

Transaction Size: $100M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert